Curative Biotechnology (OTCMKTS:CUBT) and Equillium (NASDAQ:EQ) Critical Comparison

Equillium (NASDAQ:EQ) and Curative Biotechnology (OTCMKTS:CUBT) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, analyst recommendations, valuation, profitability, institutional ownership, risk and earnings.

Valuation & Earnings

This table compares Equillium and Curative Biotechnology”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Equillium	$4.39 million	27.59	-$8.07 million	($0.62)	-3.21
Curative Biotechnology	N/A	N/A	N/A	N/A	N/A

Curative Biotechnology has lower revenue, but higher earnings than Equillium.

Risk and Volatility

Equillium has a beta of 1.81, meaning that its share price is 81% more volatile than the S&P 500. Comparatively, Curative Biotechnology has a beta of 1.4, meaning that its share price is 40% more volatile than the S&P 500.

Profitability

This table compares Equillium and Curative Biotechnology’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Equillium	N/A	-148.79%	-109.44%
Curative Biotechnology	N/A	N/A	N/A

Insider & Institutional Ownership

27.0% of Equillium shares are held by institutional investors. 31.6% of Equillium shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Analyst Recommendations

This is a breakdown of current ratings for Equillium and Curative Biotechnology, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Equillium	1	2	1	0	2.00
Curative Biotechnology	0	0	0	0	0.00

Equillium presently has a consensus target price of $3.00, indicating a potential upside of 50.75%. Given Equillium’s stronger consensus rating and higher probable upside, equities analysts clearly believe Equillium is more favorable than Curative Biotechnology.

Summary

Equillium beats Curative Biotechnology on 7 of the 9 factors compared between the two stocks.

About Equillium

Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a first-in-class monoclonal antibody that targets the immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase I clinical trial for the treatment of ulcerative colitis; and Phase I clinical trial for the treatment of lupus nephritis. It also develops EQ101 completed phase 1/2 for treatment of cutaneous T cell lymphoma and alopecia areata; and EQ302 to treat gastrointestinal indications. In addition, it serves dermatology, gastroenterology, rheumatology, hematology, transplant science, oncology, and pulmonology area. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. Equillium, Inc. was incorporated in 2017 and is headquartered in La Jolla, California.

About Curative Biotechnology

Curative Biotechnology, Inc., a development-stage biomedical company, focuses on novel treatments for rare diseases. The company focuses on therapies with potentially accelerated development paths as a result of the disease, the nature of the therapeutic itself, or the stage of clinical development. Its pipeline candidates include CURB906, an antibody-drug conjugate for targeting CD56 positive brain tumors; and IMT504, a novel immune therapy to treat rabies. The company has an agreement with Mid-Atlantic BioTherapeutics, Inc. to develop the COVID-19 vaccine. Curative Biotechnology, Inc. was founded in 1995 and is based in Boca Raton, Florida.